Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ellume
Complaint Alleges Ellume Failed To Pay Refunds After Class I Recall Of OTC COVID-19 Tests
Complaint filed in Maryland federal court says Australian firm, which received more than $230 from US government to boost production of its OTC COVID-19 diagnostic tests available to US consumers, should’ve offered refunds to consumers who bought tests the company has recalled due to false positive tests.
Ellume Faces Class-Action Suit After Class I Recall Of COVID-19 Tests
The lawsuit, filed in Maryland federal court, says Ellume should’ve offered refunds to people who bought later-recalled COVID-19 tests from the company.
Recall Of Millions Of Ellume COVID-19 Tests High-Risk Class I, FDA Says
Ellume recalled 2,212,335 of the home tests because there’s a chance they can give false-positive results.
Digital Health Roundup, March 2021: Record-Breaking Funding; Exec Chats With Medtronic, Edwards LifeSciences
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news to date.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.